Thermal liquid biopsy (Tlb): A predictive score derived from serum thermograms as a clinical tool for screening lung cancer patients by Rodrigo, Alberto et al.
cancers
Article
Thermal Liquid Biopsy (TLB): A Predictive Score
Derived from Serum Thermograms as a Clinical Tool
for Screening Lung Cancer Patients
Alberto Rodrigo 1, Jorge L. Ojeda 2, Sonia Vega 3, Oscar Sanchez-Gracia 4, Angel Lanas 5,6,7,8,
Dolores Isla 6,9, Adrian Velazquez-Campoy 3,6,8,10,11,* and Olga Abian 3,6,8,10,12,*
1 Medical Oncology Department, Hospital Arnau de Vilanova, 25198 Lleida, Spain
2 Department of Statistical Methods, Universidad de Zaragoza, 50009 Zaragoza, Spain
3 Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Units IQFR-CSIC-BIFI, and
GBsC-CSIC-BIFI, Universidad de Zaragoza, 50018 Zaragoza, Spain
4 Enrique Val, 50011 Zaragoza, Spain
5 Department of Medicine, University of Zaragoza, 50009 Zaragoza, Spain
6 Aragon Institute for Health Research (IIS-Aragon), 50009 Zaragoza, Spain
7 Servicio de Aparato Digestivo, Hospital Clinico Universitario Lozano Blesa, 50009 Zaragoza, Spain
8 Biomedical Research Networking Center in Digestive and Hepatic Diseases (CIBERehd),
28029 Madrid, Spain
9 Medical Oncology Department, Hospital Clinico Universitario Lozano Blesa, 50009 Zaragoza, Spain
10 Department of Biochemistry and Molecular and Cell Biology, Universidad de Zaragoza,
50009 Zaragoza, Spain
11 Fundacion ARAID, Government of Aragon, 50018 Zaragoza, Spain
12 Aragon Health Sciences Institute (IACS), 50009 Zaragoza, Spain
* Correspondence: adrianvc@unizar.es (A.V.-C.); oabifra@unizar.es (O.A.);
Tel.: +34-976762996 (A.V.-C.); +34-976555417 (O.A.)
Received: 27 May 2019; Accepted: 17 July 2019; Published: 19 July 2019


Abstract: Risk population screening programs are instrumental for advancing cancer management
and reducing economic costs of therapeutic interventions and the burden of the disease, as well
as increasing the survival rate and improving the quality of life for cancer patients. Lung cancer,
with high incidence and mortality rates, is not excluded from this situation. The success of screening
programs relies on many factors, with some of them being the appropriate definition of the risk
population and the implementation of detection techniques with an optimal discrimination power
and strong patient adherence. Liquid biopsy based on serum or plasma detection of circulating tumor
cells or DNA/RNA is increasingly employed nowadays, but certain limitations constrain its wide
application. In this work, we present a new implementation of thermal liquid biopsy (TLB) for
lung cancer patients. TLB provides a prediction score based on the ability to detect plasma/serum
proteome alterations through calorimetric thermograms that strongly correlates with the presence of
lung cancer disease (91% accuracy rate, 90% sensitivity, 92% specificity, diagnostic odds ratio 104).
TLB is a quick, minimally-invasive, low-risk technique that can be applied in clinical practice for
evidencing lung cancer, and it can be used in screening and monitoring actions.
Keywords: liquid biopsy; lung cancer; serum sample; differential scanning calorimetry; generalized
linear models; cancer screening program
Cancers 2019, 11, 1012; doi:10.3390/cancers11071012 www.mdpi.com/journal/cancers
Cancers 2019, 11, 1012 2 of 20
1. Introduction
1.1. Liquid Biopsy (LB)
Solid tumors exhibit remarkable complexity, with large cellular heterogeneity, where different
types of cells (cancer cells, fibroblasts, adipocytes, endothelial cells, immune cells, and the extracellular
matrix (ECM)) coexist [1,2]. All these components extensively interact and are responsible for cancer
development, suggesting that cancer cells are not completely autonomous. The development of cancer
strongly depends on the interplay of surrounding cells and non-cellular components which are present
in the microenvironment. All this is crucial for establishing an appropriate niche for the tumor to
develop in, regulating its growth, and allowing cancer cells to evolve. Therefore, the interaction
between tumor cells and the microenvironment is the basis for the development, progression, and
therapy response in solid tumors [3].
The ECM is constantly being remodeled; its cells display constant activity, which in turn depends
to a large extent on the extracellular matrix itself [2]. The result of this remodeling process is the release
of different ECM components into the bloodstream, which represents the main source for a variety of
biomarkers reporting on tumor characteristics, growth, and development [4,5].
Liquid biopsy (LB) is a technology based on the sampling and analysis of non-solid biological
tissue for the diagnosis, prognosis, and prediction of a therapeutic response of a certain illness, without
the need for costly or more invasive procedures. The interest of LB clinical implementation for cancer
diagnosis has recently increased and many bibliographical references on this topic can be found [6–8].
The optimal application of LB in clinical practice requires solving some aspects that may limit its
implementation. Some aspects are related to standardization of the pre-analytical and analytical process;
for example, the sample should be subjected to as little manipulation as possible and its preservation
must be controlled in order to guarantee the stability of the biomarkers of interest [9]. Other aspects
are related to the expected high sensitivity for the analytical procedure in order to be used in the
early detection of cancer, allowing small tumors, undetectable by conventional imaging techniques,
to be identified [10,11]. Finally, specific biomarkers for each type of cancer must be identified and
quantified [12]. Efforts of researchers and companies developing LB approaches are focused on these
aspects [6,7].
Several major obstacles complicate the application and interpretation of LB in clinical practice, as
follows: (1) mapping of tumor biochemical, histological, and immunological features and LB parameters
for obtaining information on a potential tumor; (2) handling and measuring of the biological sample; (3)
obtaining enough of a sample for measurement; (4) identifying specific and non-specific tumor-related
biomarkers for patient classification and prioritization; and (5) cell population heterogeneity in
solid tumors.
1.2. Thermal Liquid Biopsy (TLB)
In the last decade, differential scanning calorimetry (DSC) analysis of blood plasma has arisen as a
promising approach for the discrimination of healthy and cancer patients [13–16]. A DSC thermogram
reflects the global denaturation profile for all major blood plasma proteins and their potential interactions
with other blood plasma constituents (proteins and metabolites). The composition of blood serum
can be significantly altered, either by the up- or down-regulation of proteins, or by the release of
disease-related metabolites into the bloodstream. A plasma thermogram would reflect the distortion
caused by the tumor. Therefore, this technique could be employed as a clinical test for diagnosing,
classifying, and monitoring patients, since the thermograms from a diseased subject and a healthy
subject can be considerably different [17,18]. Our group has previously shown that DSC can be applied
for classifying and staging gastric adenocarcinoma patients and monitoring melanoma patients during
their treatment [19].
These previous works represent the proof of principle for implementing what we have termed
“thermal liquid biopsy” (TLB, i.e., DSC thermogram analysis of a serum sample) as a valuable approach
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for a personalized diagnostic assessment of cancer patients. This methodology would provide physicians
with a closer and personalized monitoring protocol to help in assessing patient health status and to
facilitate the decision-making process. Combining thermograms with a multiparametric analysis allows
for definitive single diagnostic values to be obtained, which can then be compared with the control
reference values. The provided score is a measure of the alteration of the blood plasma proteome, which,
as reported here, shows a strong correlation with the presence of lung cancer. TLB can be regarded
as a minimally-invasive, low risk, quick technique complementary to current imaging modalities,
establishing congruent surveillance schemes by performing routine imaging as currently prescribed
(e.g., 2–4 times a year), while proposing more frequent TLB tests (e.g., monthly or bimonthly).
1.3. Lung Cancer
According to the Global Cancer Observatory data [20], lung cancer ranked first in 2018 as the
cancer with the highest worldwide incidence and mortality rate in men and the second in women
(more deaths than colon, breast, and prostate cancers combined). This represents a total of 2 million
new cases and 1.7 million deaths in 2018.
Successful therapeutic treatment or surgical intervention of the tumor require appropriate and
accurate disease prognosis and early stage detection (I−IIIB); however, a lack of relapse after removal of
the tumor or absence of metastasis cannot be guaranteed. Different actions have been implemented as
a means of reducing the social and health impact of lung cancer, as follows: (1) prevention campaigns
leading to a reduction in tobacco consumption; and (2) screening programs in risk populations for
reducing lung cancer mortality by detecting the disease in its early stages, when tumors can be
surgically resected or treated with chemotherapy with a better prognosis.
Among the imaging techniques employed for lung cancer identification and characterization,
low-dose computed tomography (LDCT) was introduced in a United States National Lung Screening
Trial, achieving a 20% reduction in specific mortality. This study showed that LDCT had a greater
sensitivity than a chest X-ray for lung cancer diagnosis [21]. However, this screening protocol based on
LDCT presented a series of severe drawbacks, such as the high false positive rate, uncertainty about the
suitable periodicity between follow-up tests, and the cost-effectiveness of the protocol in individuals at
a high risk of suffering from lung cancer [22].
In order to improve the cost-effectiveness of the test, studies have been carried out to define, in a
very precise way, the selection criteria for the risk population which the screening is aimed at, and
which subpopulation would benefit the most from it [23,24]. Epidemiological factors must be taken
into account, in addition to age and tobacco consumption.
In this sense, TLB is presented as a complementary method that, combined with imaging
techniques, can serve to improve the sensitivity and specificity of the screening method if adopted in
clinical practice [25–27].
1.4. TLB for Lung Cancer Diagnosis and Monitoring
Compared to current technological procedures for inferring information on the physiological
characteristics of tumors, including liquid biopsy based on circulating tumor cells and DNA, the
advantages of TLB are the following:
(1) Simple and quick sample handling: once serum from the blood sample is obtained, it can be
stored, frozen, and TLB-measured by simple dilution in a phosphate-buffered saline solution
after thawing (when stored at −80 ◦C, samples remain after several freezing/thawing cycles);
(2) High sensitivity measurement: TLB is able to detect changes in the serum composition (down-
or upregulation of major serum proteins, presence of interacting tumor-related metabolites,
tumor-related posttranslational modification of major serum proteins) at early stages of the
illness, even when lesions are not visible using imaging techniques [18];
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(3) Broad clinical scope: TLB can be applied to different types of cancers, since the analytical
detection method is based on real-time observation of the tumor-induced altered metabolic
state of the serum of a given subject compared to that of healthy subjects (that is, TLB does not
detect any specific tumor-related component);
(4) Quasi-real-time monitoring: TLB assesses the current proteome serum health status, instead of
providing a cancer risk evaluation based on genetic biomarkers.
TLB can be used to boost the adherence of patients to surveillance actions in a given population and
to increase the frequency of evaluation procedures by reducing the monitoring time interval without a
significant increase in economic cost or burden/risk for the patient, while providing diagnostic value for
a patient's current disease state. A high positive association between clinical groups and TLB assessment
offers advantages over current diagnosis techniques (e.g., LDCT imaging), providing a powerful
diagnostic and monitoring approach with a minimally-invasive, low-risk, low-cost clinical test for lung
cancer. Promising future applications, such as implementation within screening programs, could be
developed from TLB. As a first step towards this goal, our main objective in this work is to determine
the ability of TLB to discriminate between healthy controls (HC) and lung cancer patients (LCP).
2. Results
2.1. TLB Serum Thermograms for HC and LCP Individuals
Serum thermograms were measured for each individual belonging to HC (n = 85) and LCP
(n = 114) groups. Figure 1 shows representative thermograms for healthy and diseased subjects.
The homogeneity of serum thermograms within the HC group, as well as their heterogeneity within
the LCP group, is remarkable. Moreover, significant differences in the TLB thermograms of healthy
and diseased subjects are apparent. The application of the deconvolution procedure (see Materials and
Methods) provides the multiparametric set representing the basis for the statistical methodology for
classifying and discriminating between HC and LCP individuals.
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patient (LCP) indivi uals. (A) Average TLB thermogram calculated with all subjects belonging to the
HC group (continuous line) is shown together with the standard deviation of the thermograms at each
temperature (shaded region). (B) TLB thermogram for a healthy subject (black line) compar d to three
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2.2. Analysis of Individual TLB-Derived Parameters
As a preliminary statistical evaluation of the ability of the different parameters to classify
individuals into HC and LCP groups, we determined the main quartiles Q1, Q2, and Q3 (that is, the
median and the first and third quartiles) for the distribution of each TLB-derived parameter within
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these two groups. Table 1 shows these statistical indexes for HC and LCP groups (see also Table S1 and
Figure S1).
Table 1. Quartiles of individual thermal liquid biopsy (TLB)-derived parameters in healthy control
(HC) and lung cancer patient (LCP) groups.
Group HC Group LCP Group
Parameter Q1 Q2 Q3 Q1 Q2 Q3
Tav 67.59 67.95 68.39 67.78 68.16 68.71
G1 0.1333 0.2588 0.3521 0.2899 0.4436 0.5662
AUCn2 19.86 26.89 43.66 18.72 24.20 36.15
APn2 0.6233 1.127 2.762 0.4884 0.9303 1.902
AUCn3 20.39 22.76 25.94 21.59 25.76 33.09
APn3 0.5914 0.8038 1.016 0.7416 0.9723 1.551
AUCn4 28.69 39.55 51.97 25.74 33.30 46.76
APn4 1.457 2.416 4.028 0.9898 1.619 3.508
AUCn5 39.20 43.20 50.93 36.73 47.69 63.12
APn5 2.265 2.876 4.148 2.150 3.120 6.294
Dv2 1.057 1.190 1.867 1.094 1.204 1.393
Dv3 1.008 1.043 1.121 1.014 1.072 1.509
Dv4 1.043 1.173 1.375 1.081 1.184 1.3333
Dv5 1.003 1.035 1.160 1.025 1.197 1.480
In order to visually inspect and explore single-parameter dissimilarities between HC and LCP
groups, size effects were estimated through an adapted Cohen d index, calculated as the difference
between the median values normalized by the pooled (weighted-average) interquartile range for each
parameter (that is, median values and interquartile ranges were employed, instead of average values
and standard deviations). Therefore, not only the difference in the median for each parameter is
evaluated, but also how large this difference is compared with the parameter dispersion. Figure 2
shows the normalized median difference for each parameter, and seven parameters (Tav, G1, AUCn3,
APn3, AUCn4, APn4, and Dv5) emerge individually as the statistically most important parameters for
distinguishing both groups.
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Figure 2. Adapted Cohen d index as a measure of size effect between healthy control (HC) and lung cancer
patient (LCP) groups (differe ce between the m dian values normalized by the po led interquartile ra e)
for the individual parameter der v d from TLB serum thermograms. Some f the parameters show arge
differences between the two groups: Tav, G1, AUCn3, APn3, AUCn4, APn4, and Dv5 (a threshold value of
±0.25 is indicated by the dotted line).
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To evaluate the predictive capabilities of each of the TLB-derived parameters, we performed
a Receiver Operating Characteristic (ROC) curve analysis. The main idea behind ROC analysis is
the identification of an optimal cut-off value for each of the parameters that might be employed for
classifying subjects as healthy or diseased, by simultaneously maximizing the statistical sensitivity and
specificity. To establish the optimal cut-off, we have considered the Youden method, one of the most
common methods for ROC optimization [28]. Table 2 shows the result of applying the Youden method
to the HC and LCP groups. The success rate or accuracy is the probability of correctly classifying
subjects as healthy (unaltered TLB thermogram and belonging to the HC group) or diseased (altered
TLB thermogram and belonging to the LCP group), while the sensitivity and the specificity are the
percentage of true positives (positive according to TLB and belonging to the LCP group) and true
negatives (negative according to TLB and belonging to the HC group), taking their respective LCP and
HC groups as a reference.
Table 2. Receiver Operating Characteristic (ROC) analysis for individual thermal liquid biopsy (TLB)-
derived parameters.
Parameter Success Rate Sensitivity Specificity Threshold Trend
Tav 57.8 61.4 52.9 68.0 ↓
G1 71.4 63.2 82.3 0.37 ↓
AUCn2 53.8 48.2 61.2 23.9 ↑
APn2 56.8 62.3 49.4 1.23 ↑
AUCn3 63.8 59.7 69.4 24.9 ↓
APn3 61.8 64.0 58.8 0.88 ↓
AUCn4 58.8 53.5 65.9 34.0 ↑
APn4 59.3 54.4 65.9 1.82 ↑
AUCn5 61.3 57.9 65.9 45.4 ↓
APn5 58.3 43.9 77.6 4.26 ↓
Dv2 53.3 58.8 45.9 1.17 ↓
Dv3 58.8 41.2 82.4 1.14 ↓
Dv4 56.3 65.8 44.5 1.11 ↓
Dv5 63.3 59.7 68.2 1.08 ↓
Note: ROC analysis using the Youden method allowed the threshold to be calculated for any individual parameter
for classifying subjects as healthy (negative, unaltered TLB thermogram) and diseased (positive, altered TLB
thermogram). The trend symbol indicates the direction for classification as a healthy subject: ↑↓ means that, in
general, subjects classified as healthy (negative result according to TLB) showed values that were larger/smaller
than the indicated threshold.
From Table 2, it is apparent that G1, AUCn3, APn3, AUCn5, and Dv5 are the most successful
individual parameters (high success rate, sensitivity and specificity values) in correctly classifying the
subjects as healthy or diseased according to individual ROC analysis.
2.3. Constructing a Predictive/Classifying Score for Lung Cancer Condition with GLM
Although some of the individual TLB-derived parameters exhibit a good performance regarding
subject classification, the combined use of several parameters (as suggested from the fact that the
two preliminary approaches have provided slightly different subsets of relevant parameters) might
significantly improve the performance of the classification score if the goal is applying TLB in clinical
practice. Three models, with each using a different set of parameters, were considered. Model 1 was
constructed based on Tav, G1, AUCni, and APni; model 2 was constructed based on Dvi; and model 3
considered all 14 parameters.
We conducted a comparative analysis of four tools: Binomial Generalized Linear Model with Logistic
Regression (GLM), Linear Discrimination Analysis (LDA), Support-Vector Machine for classification
(SVM), and Näive Bayes Classifier (NBC). The performance of these four tools was as follows: GLM
> SVM > LDA > NBC, though SVM and GLM were always very close (Table S2). As is shown in the
Supplementary Materials, GLM and SVM perform similarly with model 3, which is apparently the best
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model. In addition, the interpretation of the predictive model with SVM is not as straightforward as
that of the model with GLM. For these reasons, we will only consider the GLM framework.
A comparison of the three models (1–3) was conducted using GLM. Because the Dvi parameters
are non-linear functions of other individual TLB-derived parameters, establishing whether or not model
3 (all 14 individual parameters) represents a significant improvement for predicting a health/disease
condition was a required step.
When GLM is applied to model 1, only the individual parameters Tav, G1, and AUCn3 have
statistical significance (p-values < 0.05). The results of this analysis are shown in Table 3. The z-value
is the regression coefficient divided by the standard error obtained by GLM. As a rule of thumb, a
cut-off value of 2 (which approximately corresponds to a two-sided hypothesis test with a significance
level of α = 0.05) indicates whether the corresponding parameters are important (if the absolute value
of the z-value > 2, then its corresponding GLM coefficient is non-negligible, i.e., not null, and the
parameter is important and meaningful for predicting the presence/absence of lung cancer). On the other
hand, when GLM is applied to model 2, only the individual parameters Dv3 and Dv5 have statistical
significance (p-values < 0.05). Finally, when GLM is applied to model 3, the parameters showing
statistical significance are mainly the ones that were meaningful in the previous models: Tav, G1, AUCn3,
AUCn4, APn4, AUCn5, and Dv4. Interestingly, this set of parameters does not exactly coincide with the
set previously identified by the preliminary statistical analysis (Tables 1 and 2, Figure 2).
Table 3. Summary of the application of Binomial Generalized Linear Model with Logistic Regression
(GLM) to the three models.
Model Parameter z-Value p-Value
Model 1
Tav −5.14 0.00000
G1 −6.38 0.00000
AUCn2 −1.18 0.23689
APn2 0.931 0.35192
AUCn3 −2.59 0.00949
APn3 0.975 0.32937
AUCn4 1.38 0.16735
APn4 −1.28 0.20197
AUCn5 1.36 0.17247
APn5 1.46 0.14450
Model 2
Dv2 1.29 0.19585
Dv3 −2.14 0.03265
Dv4 −1.22 0.22283
Dv5 −1.96 0.04993
Model 3
Tav −4.63007 0.00000
G1 −6.30023 0.00000
AUCn2 −1.45263 0.14633
APn2 1.68493 0.09200
AUCn3 −2.84924 0.00438
APn3 1.05694 0.29054
AUCn4 2.80208 0.00508
APn4 −2.36746 0.01791
AUCn5 2.15199 0.03140
APn5 −1.31683 0.18789
Dv2 −1.65683 0.09755
Dv3 −0.70715 0.47947
Dv4 −2.26054 0.02379
Dv5 0.04718 0.96237
Because the three models (1–3) apparently perform differently, we need to establish which one
should be finally employed. The model equivalence tests based on the likelihood ratio (Table 4) show
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that model 1 is statistically equivalent to the complete model. In addition, Bayesian and Akaike
Information Criteria confirm that model 1 and model 3 are rather similar.
Table 4. Model comparison based on the likelihood ratio and on Akaike and Bayesian information criteria.
Indexes Model 1 Model 2 Model 3
Degrees of Freedom −4 −10 n.a.
Residual Degrees of Freedom 188 194 184
Residual Deviance 127 241 118
Equivalency with model 3 P(>χ2) 0.06269 0.00000 n.a.
Akaike Information Criterion 149 251 148
Bayesian Information Criterion 185 267 198
n.a.: not applicable.
If we compare the performance of the three models to predict lung cancer for the individuals
within HC and LCP groups, as shown in Table 5, model 3 performs better than the other two models
in terms of the success rate, sensitivity, and specificity (Table 5). False negatives are lung cancer
patients with predicted probability score (PS) scores higher than 0.5, while false positives are healthy
individuals with predicted PS scores lower than 0.5. The sensitivity and specificity are defined as
the true positive and true negative rates considering the LCP group and HC group, respectively, as a
reference. The diagnostic odds ratio of models 1, 2, and 3 are 54, 5, and 104, respectively.
Table 5. Model comparison based on the ability to classify subjects.
Model Success Rate Sensitivity Specificity
Model 1 88 89 87
Model 2 69 73 65
Model 3 91 90 92
LOO Test Success Rate Sensitivity Specificity
Model 1 86 86 87
Model 2 65 60 68
Model 3 87 86 88
The predictions used to build the previous table were made for those same individuals that were
used to fit the model. In order to reduce any possible bias, we carried out a leave-one-out (LOO) study
to get a more realistic idea of the performance of the proposed models (Table 5). In this LOO study, the
probability of being healthy/diseased for an individual is calculated by fitting the model with all the
data except that specific subject. While LOO produces as many sets of fitted parameters and as many
PS score predictions as the dataset size (total number of HC and LCP individuals), we focus on this PS
score to predict the subject condition and, then, we compute the overall success rate, the sensitivity,
and the specificity. This is a type of cross-validation equivalent to considering each subject as a testing
subject, while using all other subjects as a training set to make the predictions.
As a fixed set of parameters is required to define the complete model, we will only consider model
3 based on the complete set of TLB-derived parameters in order to calculate the probability (PS score)
of an individual being healthy or suffering from lung cancer given the TLB thermogram. It must be
emphasized that this probability, as a diagnostic tool, has to be understood as an assessment index: the
smaller the PS score (closer to 0) for an individual, the higher the probability the given subject suffers
from lung cancer; the larger the PS score (closer to 1) for an individual, the higher the probability the
individual is healthy. It is important to emphasize that the PS score is not the probability of being
healthy or suffering from lung cancer, but the probability of having an unaltered/altered protein serum
TLB thermogram; an altered TLB thermogram might be induced or caused by lung cancer. That
correlation between a lung cancer condition and altered TLB thermogram is supported by the good
performance of our model in classifying and discriminating HC and LCP groups.
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It is clear that the complete model (model 3) is the best one, achieving a 91% success rate in
correctly classifying individuals, 8% false positive rate (i.e., classifying as diseased a healthy subject),
and 10% false negatives (i.e., classifying as healthy a diseased subject). Even though not all TLB-derived
parameters seem to be statistically significant regarding the ability to classify individuals, we decided
to keep all parameters in the model (that is, using model 3).
Figure 3 shows the distribution of the PS score calculated with model 3 using GLM. There is a
marked difference in the distribution of the PS score for HC and LCP groups: in HC, the median PS score
is Q2 = 0.88 (Q1 = 0.70, Q3 = 0.94), while in LCP, the median PS score is Q2 = 0.05 (Q1 = 0.01, Q3 = 0.18).
This provides a visual assessment for the quality and performance of the discriminating power of
the PS score and the strong correlation between the PS score (ability to identify an unaltered/altered
serum TLB thermogram) and the absence/presence of lung cancer. The distributions of PS for HC and
LCP groups are very different; the difference in medians for those groups is statistically significant
(p < 10−15). According to these data, 75% of the LCP subjects have a PS score below 0.18, while 75% of
the HC subjects have a PS score above 0.70, resulting in an effective PS score distance of 0.52 between
these two groups. Similarly, because the medians for the HC group and LCP group are 0.88 and 0.05,
respectively, the difference in PS score between the 50% of HC subjects with the highest PS score
(i.e., less altered TLB thermogram) and the 50% of LCP subjects with the lowest PS score (more altered
TLB thermogram) is larger than 0.8. This gives an idea of the potential of the PS score for discriminating
between HC and LCP subjects.
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Figure 3. Distribution of the probability score (PS) score within healthy individuals (HC group) and
lung cancer patients (LCP group). The lines represent an equivalent Gaussian distribution. The PS
score threshold for discriminating between an unaltered (associated with healthy status) and altered
(associated with lung cancer status) serum proteome thermal liquid biopsy (TLB) thermogram is 0.5
(grey dotted line). It can be observed that seven healthy subjects are assigned a PS score lower than 0.5
(8% false positive rate) and 11 lung cancer subjects are assigned a PS score higher than 0.5 (10% false
positive rate).
The aim of the next sections is to explore the properties of the PS score (probability of having an
unaltered/altered TLB thermogram, which is related to being healthy or suffering from lung cancer)
through a detailed analysis of the PS score applied to HC and LCP groups. We studied the values of
the PS score according to the information available for the individuals on either their clinical history
or condition in both HC and LCP groups of individuals. Therefore, we sought to find out whether
there are any correlations between the PS score and any of the personal and clinical history parameters
(gender, age, diagnosis, stage, treatment, response, survival, smoker, and number of cigarette packs
per year).
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2.4. PS Score in Healthy Subjects (HC Group)
In order to study the behavior of the proposed PS score, and taking into account its asymmetry
for both HC and LCP groups, we have developed a small descriptive analysis using quartiles and the
rank-based Kruskal–Wallis test to address if the distribution by group is the same or not. It can be seen
(Figure 4, Table S3 and Table 6) there are no significant differences in the distribution of PS score in the
HC group according to the gender and age of the individuals (p-value > 0.05; Table S3). Therefore, in
healthy individuals, the probability of having a normal/altered TLB thermogram does not depend on
either gender or age. When looking at the behavior of the classification established by the PS score
(i.e., whether PS score > threshold = 0.5 or not), a few subjects (7) are classified as having an altered
TLB thermogram (false positives), but they are older than 40, and indeed four of them are older than
50 (Table 6). There is no significant departure from independence between the variables involved.
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Figure 4. Distribution of the probability score (PS) within healthy individuals (HC group, black) and
lung cancer patients (LCP group, red) according to gender (A) and age (B). The box-plot diagrams
indicate Q1, Q2, and Q3, together with the average value (square). The number below each box is
the number of subjects within each subgroup. The p-value (Kruskal–Wallis test) indicates there is no
statistically significant difference between subcategories (gender and age) within HC and LCP groups
(p > 0.05).
Table 6. Contingency tables for gender and age (probability score (PS) threshold = 0.5).
Group Gender PS > 0.5 True Negatives PS < 0.5 False Positives p-Value
Healthy Controls Men 43 (96%) 2 (4%) 0.2460Women 35 (88%) 5 (12%)
Gender PS > 0.5 False Negatives PS < 0.5 True Positives p-Value
Lung Cancer Patients Men 8 (8%) 87 (92%) 0.2394Women 3 (16%) 16 (84%)
Age PS > 0.5 True Negatives PS < 0.5 False positives p-Value
Healthy Controls
< 40 32 (94%) 2 (6%)
0.3894
40–50 17 (100%) 0 (0%)
50–60 14 (82%) 3 (18%)
60–70 15 (88%) 2 (2%)
Age PS > 0.5 False Negatives PS < 0.5 True Positives p-Value
Lung Cancer Patients
40–50 1 (10%) 9 (90%)
0.04748
50–60 5 (23%) 17 (77%)
60–70 5 (9%) 49 (91%)
70–iii 0 28 (100%)
Note: p-Values were calculated according to Fisher’s independence test.
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2.5. PS score in Lung Cancer Patients (LCP)
It is clear that the PS score for those individuals with lung cancer (LCP group) is dramatically
smaller than the PS score for healthy subjects (HC group), indicating an altered TLB thermogram
(Figure 4, Table S3 and Table 6). As it occurred in the HC group, there are no significant differences
in the PS score according to gender or age (p-value > 0.05; Table S3). However, when looking at the
behavior of the classification established by the PS score (i.e., whether PS score > threshold = 0.5 or
not), a few subjects (11) were classified as having an unaltered TLB thermogram (false negatives), and
most of them are older than 50 (Table 6). There is no significant departure from independence between
the variables involved, except for a marginal effect of age in lung cancer patients.
Once it has been established that the PS score is not significantly affected by gender and age, the
next step is to explore whether or not the PS score provides information about the stage and particular
conditions of the cancer suffered by an individual from the LCP group (i.e., whether it shows some
correlation with clinical history information).
There is no statistically significant relationship between the PS score and diagnostic, tumor stage,
treatment, and clinical response (p > 0.05) (Table S4). However, tumors diagnosed as squamous or
small cell carcinoma show very small PS scores compared to adenocarcinoma or other non-small
cell tumors (Figure 5, Table S4). Only a few subjects (11) were classified as having an unaltered TLB
thermogram (false negatives), and they mainly correspond to adenocarcinoma (8), and stages III (2)
and IV (9) (Table 7). Once again, there is no significant departure from independence between the
variables involved.
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Figure 5. Distribution of the probability score (PS) within healthy individuals (HC group, black) and lung
cancer patients (LCP group, red) according to (A) ia n stic (AC: adenocarcinoma, SC: squ mous cell
lung cancer, SCLC: small ell lung cancer, NSLC: other on-small cell lung cancer), (B) sta e, (C) treatment
(ACT: adjuvant chemotherapy, NACT: neoadjuvant chemotherapy, PCT: palliative chemotherapy, RCT:
radio-chemotherapy), and (D) response (SD: stable disease, D: death, P: progression, CR: complete
response, PR: partial response). The box-plot diagrams indicate Q1, Q2, and Q3, together with the average
value (square). The number below each box is the number of subjects within each subgroup. The p-value
(Kruskal–Wallis test) indicates there is no statistically significant difference between subcategories
(diagnostic, stage, treatment, and response) within HC and LCP groups (p > 0.05).
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Table 7. Contingency table for clinical history information (probability score (PS) threshold = 0.5).
Group Diagnostic PS > 0.5 False Negatives PS < 0.5 True Positives p-Value
Lung Cancer
Patients
Adenocarcinoma 7 (16%) 36 (84%)
0.1294
Squamous cell carcinoma 2 (6%) 30 (93%)
Small cell carcinoma 1 (3%) 34 (97%)
Other non-small cell carcinoma 1 (25%) 3 (75%)
Stage PS > 0.5 False Negatives PS < 0.5 True Positives p-Value
Lung Cancer
Patients
II 0 (0%) 6 (100%)
0.8541III 2 (7%) 28 (93%)
IV 9 (12%) 69 (88%)
Note: p-Values were calculated according to Fisher’s independence test.
3. Discussion
The utility of TLB thermograms in classifying gastric patients and monitoring melanoma cancer
patients has been previously shown [18,19]. For these tasks, two similar approaches based on the
deconvolution of serum thermograms into individual temperature-induced transitions according to
a phenomenological interpretation of the apparent average excess heat capacity, CP, of the serum
sample were applied. From that deconvolution, a set of thermogram-derived primary parameters was
defined (Tav, G1, Ai, Tc,i, wi), and they were employed for calculating a second set of secondary or final
parameters (AUCni, APni, Dvi). In this work, we have refined the methodology by using appropriate
statistical tools for building a model with the ability to classify subjects according to a predictive score:
the probability measure of having a healthy/altered serum thermogram, which is expected to correlate
with the presence of cancer, as evidenced by previous published work [15,17–19].
This model was built using healthy individuals and lung cancer patients, with the final goal of
applying the predictive score in clinical practice for estimating the probability of suffering from lung
cancer, provided that there would be a strong correlation between an altered serum TLB thermogram
and the presence of lung cancer. Therefore, two groups of subjects were employed as a control group
(85 healthy individuals, HC) and diseased group (114 lung cancer patients, LCP).
An initial preliminary analysis of the statistical distribution of the 14 individual TLB-derived
parameters (Tav, G1, AUCni, APni, Dvi) based on the three quartiles Q1-3 suggested that Tav, G1, AUCn3,
APn3, AUCn4, APn4, and Dv5 were noticeably different between HC and LCP groups (Table 1, Figure 2).
A step forward consisted of performing an ROC analysis (Table 2) from which G1, AUCn3, APn3,
AUCn5, and Dv5 emerged as statistically relevant parameters. The fact that these two subsets only
share some elements indicates that simple analytical approaches will only provide a limited description
of the differences between TLB thermograms, and it is an indication of the potential hidden, subtle
details within the thermograms.
From a statistical point of view, there exist a range of different techniques that can be used
to predict the outcome of a binary random variable. Indeed, most of them are not only useful for
making predictions, but they also offer a way of obtaining either a probability or a sort of score for
discriminating between the two options. A good overview of these techniques and their use can be found
elsewhere [29,30]. While the main features and the motivation of these techniques are quite different,
in principle, they are all valid for our goal: elaborating a predictive score for classifying individuals
according to their TLB thermograms that correlates with the absence/presence of lung cancer.
The performances of four different predictive tools (GLM, LDA, SVM, and NBC) were compared
considering the aforementioned datasets: model 1 based on Tav, G1, AUCni, and APni; model 2 based
on Dvi; and model 3 based on the complete set of 14 parameters. GLM outperformed the other three
tools when using these three sets of parameters (see Supplementary Materials). Therefore, GLM was
selected to construct a probability score (PS) from TLB-derived parameters because it allows the fit
of different models to be built and compared based on their parameters and it could be possible to
measure the relative importance of TLB-derived parameters to classify diseased/healthy individuals.
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It is important to bear in mind that the final goal is two-fold: 1) make an appropriate classification of
healthy and diseased individuals using TLB; and 2) provide a quantitative score that can be interpreted
as the probability for a person to be in a healthy or lung cancer condition according to TLB. Therefore,
ROC techniques will not be of interest, as model comparison will not be easy beyond the performance
in terms of the classification performance.
The application of GLM revealed different subsets of statistically relevant (p < 0.05) TLB-derived
parameters for discriminating between HC and LCP groups, depending on the multiparametric models:
Tav, G1, and AUCn3 for model 1; Dv3 and Dv5 for model 2; and Tav, G1, AUCn3, AUCn4, APn4, AUCn5,
and Dv4 for model 3. Interestingly, this subset of relevant TLB parameters partially coincides with
those subsets identified with the initial preliminary analysis.
Although somewhat marginally compared to model 1, model 3 provides the best performance
using GLM. The PS score obtained with GLM and model 3 results in a 91% success rate or accuracy
in properly classifying subjects into healthy and diseased (lung cancer), 90% sensitivity (10% false
negative rate), and 92% specificity (8% false positive rate), leading to a remarkable diagnostic odds ratio
of 104. Despite the dependency of the confidence intervals (CI) on the sample size, the calculated CI95%
values for accuracy, sensitivity, sensitivity, and diagnostic odds ratio are (86%, 95%), (83%, 95%), (84%,
97%), and (39, 280), respectively. These indexes and their CI95%’s support a strong correlation between
the PS score and the absence/presence of lung cancer. In fact, the distribution of the PS score for HC
and LCP groups is very different and there is a pronounced inter-group difference in the distribution
of the PS score for HC and LCP groups: in HC, the median PS score is 0.88, while in LCP, the median
PS score is 0.05. The test for the median difference provides a p-value lower than 10-15. In addition,
the size effect for the binomial classification obtained by the PS score between the two groups can
be calculated according to the Cohen d index, which is equivalent to the strictly standardized mean
difference, and it is an evaluation index for the discriminating capability of the PS score; using the
median values for HC and LCP groups as central tendency measures and the pooled interquartile
range as a dispersion measure, a Cohen d index of 3.2 is calculated for the PS score (values larger than
2 are considered highly remarkable).
A good predictive score for clinical practice should not have any bias regarding any factor that is
not directly related to the disease it is directed at. Therefore, in our case, the PS score should not show
any differences in its distribution according to gender and age within the HC group. However, in the
LCP group, there could be some influence of gender or age in the PS score distribution if lung cancer
would exhibit specific differential features, depending on gender and age. According to the results
(Table S3, Figure 4), there is neither an influence of gender nor age on the PS score in HC and LCP
groups. Regarding the lung cancer patients, it would be reasonable to assume that gender should not
have any influence on the disease, but there might be a correlation between PS score and age, since
it is well-known that age is an important risk factor for cancer. However, the LCP group consists of
subjects already suffering from lung cancer, and, therefore, all LCP individuals already show small
PS score values. In order to observe a certain correlation between the PS score and age, we should
consider a more general set of naïve subjects (i.e., with unknown a priori classification regarding the
presence of lung cancer); then, the PS score should show a slight diminishing trend as age increases,
being that reduction is dependent on the incidence of cancer along the different age ranges.
On the other hand, it could be reasonable to expect that clinical data of patients (diagnostic, tumor
stage, treatment, and response) could have a certain influence on the distribution of the PS score.
According to the results (Table S4, Figure 5), the distribution of the PS score shows no dependence
on the type of tumor (diagnostic) or on the tumor stage. Very interestingly, although the type of
tumor (diagnostic) does not influence the distribution of the PS score, the PS score shows significantly
different values for adenocarcinoma and other non-small cell tumors (median values of 0.0672 and
0.0823, respectively), compared to squamous and small cell tumors (median values of 0.0310 and 0.0324,
respectively). It would be interesting to find out if the former types of tumor induced larger alterations
in serum proteins or metabolites (e.g., increased secretion of metabolites or exosomes), compared to
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the latter type of tumors. In addition, besides other non-small cell carcinoma, for which there are only
four cases in this study, the adenocarcinoma lung cancer presents a higher false negative rate (16%),
and this is the lung cancer type with a better prognosis. Squamous and small cell carcinoma, with the
second one being a very aggressive lung cancer type, show very low false negative rates (6% and 3%,
respectively). Among the few false negative subjects (only 11 individuals, out of 114 in the LCP group,
with a PS score higher than 0.5 and, therefore, classified as having an unaltered TLB thermogram), they
mainly correspond to adenocarcinoma (8), regarding diagnostic, and stage IV (9), regarding stage. It is
important to remember that, as adenocarcinoma is the less aggressive form of lung cancer lesion, it
would be expected to produce false negatives because of the low level of serum proteome alteration.
However, at this moment, there is no clear connection between tumor stage and alteration of the serum
proteome; it might be possible that early tumor stages are highly metabolically active, resulting in a
largely markedly altered serum proteome, whereas late stages are less metabolically active, leading to
lower levels of serum proteome alterations.
The influence of the treatment applied to the patient or the response was not analyzed because of
several reasons: (1) contrary to the diagnostic (type of tumor and stage) that depends on the physiology
and natural history of the tumor, the applied treatment depends on the decision of the oncologist
based on multiple factors; (2) the response depends on the type and stage of tumor, together with the
selected treatment, and, therefore, many interplaying factors are involved; and (3) the patient response
to the treatment was only evaluated two months after the first therapeutic intervention, and it could be
possible that a two-month interval is not enough to reliably assess and infer valuable and accurate
conclusions about the patient evolution. Therefore, a lengthier surveillance time window would be
more appropriate, with periodic TLB assessments every 2–3 months. Future studies should include
more patients with stage I and II lung cancer, in order to assess whether the stage is correlated with
the intensity of TLB serum proteome alterations and the possibility of false negatives, as well as an
additional subject group consisting of patients suffering from a chronic non-neoplastic disease as a
means to explore and compare potential alterations in serum TLB profiles unrelated to cancer.
4. Materials and Methods
4.1. Subjects and Samples
Two subject groups, healthy controls (HC group) and lung cancer patients (LCP group), were
employed to build the predictive model for lung cancer providing a patient classification score.
A comprehensive description of these two groups is shown in the Supplementary Materials.
Consecutive Spanish Caucasian patients with lung cancer (LCP) diagnosed and attended in the
Medical Oncology outpatient clinic at the Hospital Clinico Universitario Lozano Blesa in Zaragoza,
Spain, from 2015 to 2016, were invited to take part in the study. A total of 114 lung cancer patients
were grouped according to their histological type (adenocarcinoma, squamous cell carcinoma, small
cell carcinoma, and other different types of non-small cell lung cancer). Moreover, the patients were
classified based on different stages at diagnosis (from stage II to IV). Patients with a synchronous
history of other malignancies, previous cancer-related treatment, the absence of blood samples, or
refusal to participate in the study were considered non-eligible. At the time of inclusion, detailed
information was recorded concerning age, gender, smoking habits, tumor-node-metastasis stage (TNM
stage) according to the Union for International Cancer Control/American Joint Committee on Cancer
(UICC/AJCC 7th Edition) classification, the presence of metastases, the type of treatment, and the
histological subtype.
The LCP group was composed of 114 patients diagnosed with lung cancer, with an average age
of 64.6 ± 8.7. Most of the patients were men (83% men vs. 17% women) and smokers (64% of the
patients were smokers, 29% ex-smokers, and 7% never smoked). Regarding the characteristics of the
disease, the majority of the patients were diagnosed at stage IV (68%), followed by stage III (27%), and
stage II (5%). All of them were treated according to their stage (68% palliative chemotherapy, 22%
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chemo-radiotherapy, 7% adjuvant chemotherapy, and 3% neoadjuvant chemotherapy). The response
observed in our patients was a 67% controlled disease rate (40% partial response, 10% complete
response, and 17% stable disease), 13% progressed disease rate, and 20% death rate after a two-month
period. Moreover, the histological distribution is in agreement with the published literature: 37% of
adenocarcinomas, followed by 30% of small cell carcinoma, 29% of squamous cell carcinoma, and 4%
corresponding to other non-small cell lung cancer).
The HC group consisted of 85 serum samples from gender and age matched Spanish Caucasian
subjects, apparently cancer-free, with no previous history of lung cancer, from a FISABIO (Fundacion
para el Fomento de la Investigacion Sanitaria y Biomedica de la Comunitat Valenciana) biobank with
a homogeneous distribution, including gender (53% men and 47% women), with an average age of
45.2 ± 14.2.
4.2. Blood Sample Processing
Approximately 10 mL of peripheral blood from each patient and control subject was collected
in serum separator tubes for subsequent TLB analysis. Tubes were gently mixed by immediately
after blood collection and centrifuged at 3200 rpm for 10 min (Centrifuge 5702, Eppendorf, Madrid,
Spain). Separated plasma was carefully aspirated to avoid hemolysis and contamination of the
separated blood phases, and immediately stored in 0.2 mL aliquots at −80 ◦C with an alphanumeric
code for identification until analysis. All participants gave written informed consent to the study
protocol, which was previously approved and conducted in accordance with the Ethical Review Board
for Clinical Research of the Regional Government (CEIC Aragon). All experimental protocols were
approved by CEIC Aragon (Nº CP18/2015, 18/11/2015). All experiments were carried out in accordance
with the approved guidelines.
4.3. Differential Scanning Calorimetry (DSC)
The heat capacity of serum samples was measured as a function of temperature, CP(T), using a
high-sensitivity automated differential scanning VP-capillary DSC microcalorimeter (MicroCal-Malvern
Panalytical, Malvern, UK). The baseline of the instrument was routinely recorded before experiments.
Experiments were performed in diluted serum samples (1:25 in phosphate-buffered saline (PBS)) at
a scanning rate of 1 ◦C/min. Thermograms were baseline-corrected and analyzed using software
developed in our laboratory implemented in Origin 7.0 (OriginLab, Northampton, MA, USA). In order
to ensure reproducibility, replicate experiments, as well as control experiments with commercial human
serum (H4522, Sigma-Aldrich, Barcelona, Spain), were performed periodically.
4.4. Thermogram Deconvolution
We have developed a phenomenological model in which the complex thermogram was deconvoluted
using six individual transitions modeled with the logistic peak or Hubbert function [18,19]:
CP(T) = CP,0 +
i=6∑
i=1
4Aiexp
(
−T−Tc,iwi
)
(
1 + exp
(
−T−Tc,iwi
))2 (1)
where Ai is the height of each peak (equivalent to the maximal unfolding heat capacity CP,max), Tc,i is
the center of the peak (equivalent to the mid-transition temperature Tm), and wi is the width of the
peak (CP(Tc ±w) ≈ 0.8A, and CPTc ± 2w) ≈ 0.4A). The offset parameter CP,0 is an adjustable parameter
to counterbalance possible errors from baseline correction. For any given serum thermogram, eighteen
parameters (Ai, Tc,i, and wi, for each of the six individual transitions), were obtained after data analysis.
These parameters constitute the basic set of parameters from which another final set of parameters
(as indicated in the next section) is constructed for the multiparametric comparative quantitative
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methodology [18,19] aimed at establishing a classification criterion among healthy subjects and lung
cancer patients.
4.5. Multiparametric Set
The multiparametric method is based on a set of 14 parameters that were defined for the TLB
thermogram of each subject in a plasma/protein concentration-independent manner. Therefore, there is no
need for protein concentration determination and there are no hidden protein concentration dependencies.
4.5.1. Average temperature, Tav
This parameter provides the average temperature or first moment of the thermogram when
considered as a density distribution function:
Tav =
∑
j CP
(
Tj
)
Tj∑
j CP
(
Tj
) (2)
where the subscript j runs over the entire range of experimental points in the thermogram.
4.5.2. Skewness, G1
This parameter provides a measure of the asymmetry of the thermogram:
mk =
∑
j CP(Tj)(Tj−Tav)k∑
j CP(Tj)
G1 =
m3
m3/22
(3)
4.5.3. Normalized area under the curve, AUCni
This parameter provides the area under the thermogram normalized by any of the peak heights
(with i = 2–5):
AUCni =
∑
j CP
(
Tj
)
Ai
(4)
4.5.4. Normalized area of the height polygon, APni
This parameter provides the area of the irregular hexagonal diagram constructed with the heights
of the six individual peaks normalized by any of the peak heights (with i = 2–5):
APni =
s=6∑
s=1
√
3
4
AsAs+1
A2i
(5)
4.5.5. Normalized distance value, Dvi
This parameter provides the Euclidean distance from the center of the HC group ellipsoid
(set of healthy subjects), considering the reference (median) values for the set of healthy subjects,
Tav, AUCni, APni:
Dvi =
√(
Tav − Tav
Tav
)2
+
(
AUCni −AUCni
AUCni
)2
+
(
APni −APni
APni
)2
(6)
4.6. Statistical Modeling
The main goal in this work was to build an optimal TLB-derived score exhibiting a strong
correlation with a lung cancer condition which could be employed as a clinical tool for lung cancer
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assessment. That score was to be constructed using the multiparametric dataset introduced above, and
three different, but related, predictive models, with each using a different basis set of parameters, were
considered: model 1 based on Tav, G1, AUCni, and APni; model 2 based on Dvi; and model 3 based on
all 14 parameters.
These three different models were developed to address the problem of constructing a prediction
or classification score for lung cancer based on the TLB-derived parameters. In fact, that score will
represent the probability of a subject being classified as healthy/diseased according to given TLB-derived
parameters (healthy if unaltered TLB thermogram, diseased if altered TLB thermogram). Those models
were elaborated using binomial Generalized Linear Models (GLM) with logit link models, since this tool
outperformed other statistical tools in discriminating subjects into healthy and diseased (see Results and
Supplementary Materials). Because we have to predict a binary variable, the binomial GLM becomes a
suitable tool to estimate a logistic regression with the outcome being the probability of absence of lung
cancer (i.e., healthy subject) according to a given TLB thermogram.
The only difference between the three GLMs consists of the set of individual TLB-parameters
considered: (1) model 1 employs Tav, G1, AUCni, and APni; (2) model 2 employs Dvi; and (3) model 3
employs all 14 parameters. Therefore, in each of the three GLMs, a given set of TLB-derived parameters,
{pk}, is employed, and the probability score, PS, of an individual with a given thermogram (i.e., with
given TLB-derived parameters {pk}) being in a healthy condition is given by the following:
PS = P
(
healthy
∣∣∣ {pk}) = eµ({pk})1 + eµ({pk}) (7)
where µ is a linear function of the TLB-derived parameters:
µ
({
pk
})
= a0 +
∑
k=1
akpk (8)
Additionally, the coefficients {ak} are optimally estimated by means of a maximum likelihood
estimator, which in turn uses an iterative reweighted least squares algorithm or Newton’s method [29].
This probability can be interpreted straightforwardly as how likely the individual with such a TLB
thermogram is free of lung cancer, and, therefore, that probability can be used as a diagnosis criterion.
This PS score based on TLB-derived parameters classifies individuals as healthy (negative result,
PS > 0.5) and diseased (positive result, PS < 0.5) subjects.
5. Conclusions
TLB is a quick, minimally-invasive, low-risk technique that provides real-time, direct information
about the proteomic state of blood serum. Through a multiparametric data analysis, the TLB-derived
PS score (probability of having an unaltered or healthy TLB serum thermogram) has been elaborated
based on well-known statistical methods. In this work, a strong correlation between the PS score
and the absence/presence of lung cancer has been demonstrated. In addition, the PS score seems to
be an appropriate, robust, unbiased measure of proteomic blood serum alterations because it is not
influenced by gender and age, and it provides markedly different values for the probability of having an
unaltered/altered serum proteome for healthy subjects and lung cancer patients. The strong correlation
between PS score and lung cancer translates into a 91% success rate in classifying subjects, 8% false
positive rate, and 10% false negative rate, with a diagnostic odds ratio of 104. Therefore, TLB is a new
type of liquid biopsy based on serum thermograms that may be employed as a diagnosis and prognosis
tool in cancer management.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/7/1012/s1:
Figure S1: Graphical description of the HC (healthy controls) and LCP (lung cancer patients) groups; Table S1:
Main descriptive measures for the 14 TLB-derived parameters, Table S2: Comparative study of the performance of
GLM, LDA, SVM, and NBC in the three models, Table S3: PS score vs. gender and age, Table S4: PS score vs
clinical history information.
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Abbreviations
CI95% confidence interval at 95% significance level
DSC differential scanning calorimetry
ECM extracellular matrix
GLM binomial generalized linear model with logistic regression
HC healthy control group
LB liquid biopsy
LCP lung cancer patients group
LDA linear discrimination analysis
LDCT low-dose computed tomography
NBC naïve Bayes classifier
PBS phosphate-buffered saline
Q quartile
ROC receiver operating characteristic
SVM support-vector machine for classification
TLB thermal liquid biopsy
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